September 8, 2024
First-line treatment with ivonescimab led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) in patients with PD-L1-positive advanced […]
September 6, 2024
Pancreatic cancer remains one of the deadliest cancers. When the disease is caught earlier, the 5-year survival rates hover around 44%, but once the cancer metastasizes, […]
September 6, 2024
When it comes to selecting a cost-effective, first-line tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), consider the treatment goal. For survival, […]
September 5, 2024
TOPLINE: A recent study found higher incidences of exposed bone and osteoradionecrosis in patients with head and neck cancer who underwent dental extractions soon after radiotherapy, […]
September 5, 2024
Clonal hematopoiesis of indeterminate potential (CHIP) and mosaic chromosomal alterations (mCAs) are associated with an increased risk for breast cancer, and CHIP is associated with increased […]
September 5, 2024
After 8 years of service, Dana-Farber Cancer Institute president and CEO Laurie Glimcher, MD, will step down from her post on October 1, according to a […]
September 5, 2024
TOPLINE: In patients with prostate cancer, androgen receptor pathway inhibitors (ARPIs) extended the median time to no longer clinically benefitting (NLCB) to 11.1 months vs the […]
September 4, 2024
TOPLINE: Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs) show comparable survival outcomes whether they continued […]
September 4, 2024
TOPLINE: Nearly 45% of cancer survivors face financial hardship during and after their cancer care, with factors including higher social vulnerability, younger age, lower income, and […]